Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BIOCON.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BIOCON.BO and 80,000+ other tickers.
See exactly how BIOCON.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIOCON.BO and 80,000+ other tickers.
Biocon Limited is a biopharmaceutical firm engaged in the manufacturing of pharmaceutical goods, including both medicinal chemical compounds and botanical derivatives. The company's operations are segmented across Generics, innovative Novel Biologics, Biosimilars, and Research Services. Its strategic focus areas encompass critical health issues such as diabetes, oncology, immunological disorders, ophthalmology, and bone health. Furthermore, Biocon offers integrated services for the discovery, development, and production of both small and large molecular entities. With a broad international…
No recent news available.